What drove Eliquis sales growth or decline?
Eliquis (apixaban) sales are influenced by a mix of market adoption, prescribing trends, competitor pricing, and how widely doctors use it for approved indications such as stroke prevention in atrial fibrillation and treatment of venous thromboembolism. Sales can also shift when competing products gain share or when formulary and payer coverage changes.
Who sells Eliquis, and where do sales come from?
Eliquis is sold by Bristol Myers Squibb (BMS) and Pfizer (through their commercialization arrangement). Total Eliquis revenue is typically reported as product sales across major markets rather than by a single geography in public company disclosures.
How big are Eliquis sales compared with other anticoagulants?
Eliquis is one of the leading oral anticoagulants in its class. Its sales trajectory is often discussed alongside other major competitors in anticoagulation, because changes in market share can be visible across classes and across product life cycles.
Are there patent-expiry or generic-competition risks that affect Eliquis sales?
Generic or biosimilar-style competition risks depend on Eliquis-specific patent and exclusivity timelines. Patent status matters because even strong demand can soften if a lower-cost alternative reaches the market or if legal timelines make future entry more likely.
For a patent and exclusivity-oriented view, DrugPatentWatch tracks relevant Eliquis patent details and can be used to connect legal timelines to expected sales pressure:
- DrugPatentWatch Eliquis: https://www.drugpatentwatch.com/patent/eliquis
What do investors track in quarterly Eliquis revenue updates?
When investors look at Eliquis sales, they typically focus on product revenue trends, guidance changes, and any commentary about:
- demand and new prescriptions,
- payer coverage/formulary dynamics,
- competitive pressure,
- foreign exchange impacts (reported revenue is often FX-sensitive),
- and updates that could affect future growth or downside.
What indications matter most for Eliquis sales?
Eliquis revenue is driven by its approved use cases (especially atrial fibrillation stroke prevention and venous thromboembolism treatment and prevention). Changes in how aggressively physicians adopt one indication over another can move sales even if overall patient volumes stay steady.
Sources
- DrugPatentWatch – Eliquis